RESEARCH TRIANGLE PARK, N.C., July 24, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a global leader of innovative digital solutions for the operating room, announced that The Rocky Mountain Hospital for Children in Denver, Colorado, part of HCA Healthcare’s HealthONE network, has entered into an agreement to utilize a Senhance® Surgical System.
“We are thrilled to announce the first dedicated pediatric hospital placement of a Senhance® System in the United States," stated Anthony Fernando, President and CEO of Asensus Surgical. "This reflects our shared commitment to innovation and patient-centered care, with the ultimate goal of improving the lives of children undergoing surgical procedures.”
“The Senhance System, uniquely suited for pediatrics, is a valuable addition to our surgical toolkit,” said Dr. Steve S. Rothenberg at The Rocky Mountain Hospital for Children. “The System's advanced features hold promise for improving outcomes in pediatric and adolescent surgery, aligning with our commitment to preserve the benefits of minimally invasive surgery while pursuing innovation and excellence in patient care.”
The Senhance Surgical System was developed to address the challenges of pediatric surgery while preserving the benefits of minimally invasive surgery.
About The Rocky Mountain Hospital for Children
Established in 2010 and located within Presbyterian St. Luke's Medical Center in Denver, Colorado, The Rocky Mountain Hospital for Children is dedicated to delivering specialized pediatric care. The Rocky Mountain Hospital hosts over 200 subspecialty physicians covering areas such as Neonatology, Pediatric Intensive Care, Pediatric Oncology, and Pediatric Cardiology, ensuring 24/7 coverage by pediatric attending physicians. With a focus on children's healthcare, the hospital is equipped with pediatric-specific supplies and serves as a regional hub for comprehensive pediatric support throughout the Rocky Mountain region. Committed to providing compassionate healthcare, fostering innovation, and engaging with the community, The Rocky Mountain Hospital for Children remains a trusted resource for pediatric care in Denver.
About Asensus Surgical, Inc.
Asensus Surgical is revolutionizing surgery with the first intra-operative Augmented Intelligence technology approved for use in operating rooms around the world. Recognized as an award-winning leader in digital technology, Asensus is committed to making surgery more accessible and predictable while delivering consistently superior outcomes. The Company’s novel approach to digitizing laparoscopy has led to system placements globally. Led by engineers, medical professionals, and industry luminaries, Asensus is powered by human ingenuity and driven by collaboration. To learn more about the Senhance® Surgical System and the new LUNA™ System, visit www.asensus.com.
Follow Asensus
Email Alerts: https://ir.asensus.com/email-alerts
LinkedIn: https://www.linkedin.com/company/asensus-surgical-inc/
X: https://twitter.com/AsensusSurgical
YouTube: https://www.youtube.com/@AsensusSurgical
TikTok: https://www.tiktok.com/@asensus_surgical
Forward-Looking Statements
This press release includes statements relating to the Senhance Surgical System and The Rocky Mountain Hospital for Children in Denver, Colorado initiating a program with the Senhance System. These statements and other statements regarding our future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include whether Asensus Surgical and the Senhance Surgical System can improve the lives of children undergoing surgical procedures and whether the Senhance Surgical System’s advance features will improve surgical outcomes in pediatric and adolescent surgery. For a discussion of the risks and uncertainties associated with the Company’s business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 21, 2024 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
INVESTOR CONTACT:
Mark Klausner or Mike Vallie
ICR Westwicke
This email address is being protected from spambots. You need JavaScript enabled to view it.
443-213-0499
MEDIA CONTACT:
Dan Ventresca
Matter Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
617-874-5488
Last Trade: | US$0.35 |
Daily Volume: | 0 |
Market Cap: | US$94.920M |
August 13, 2024 July 23, 2024 July 16, 2024 |
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB